Immunosuppression in Surgical Patients
On this page
Direct answer
Every transplant recipient lives on a narrow ledge between rejection and infection. Maintenance immunosuppression is typically triple therapy — a calcineurin inhibitor (tacrolimus, trough levels commonly targeted around 5-10 ng/mL), an antiproliferative agent (mycophenolate mofetil or azathioprine) and low-dose prednisolone — with induction agents (basiliximab, anti-thymocyte globulin) reserved for the peri-transplant window. For the surgeon, three consequences follow: wounds heal slower and infections present with muted signs; drugs interact with everything added to the chart (azoles raise tacrolimus levels, rifampicin collapses them); and the infection timeline — surgical in month one, CMV and pneumocystis in months one to six, community later — is itself a diagnostic test. Never stop these drugs abruptly; adrenal crisis and acute rejection both await.
What you must remember
- Triple therapy backbone: tacrolimus + mycophenolate + prednisolone; tacrolimus is nephrotoxic, neurotoxic, diabetogenic and causes alopecia, while ciclosporin adds hypertension, hirsutism and gingival hyperplasia — the contrast is a favourite comparison question.
- Antiproliferatives: mycophenolate causes leucopenia, gastrointestinal toxicity and is teratogenic (contraception mandatory); azathioprine causes marrow suppression and hepatotoxicity, and with allopurinol the dose must be cut to about a quarter, because xanthine oxidase inhibition blocks 6-mercaptopurine degradation.
- mTOR inhibitors (sirolimus, everolimus): impair wound healing and anastomotic strength, cause hyperlipidaemia and pneumonitis — hold or avoid around fresh anastomoses and chest surgery.
- Infection timeline: month 1 — conventional surgical and donor-derived infections; months 1-6 — cytomegalovirus (prophylaxis with valganciclovir in D+/R− pairs), BK nephropathy, pneumocystis (co-trimoxazole prophylaxis, typically 6-12 months) and fungal infections; beyond 6 months — community-acquired organisms.
- Malignancy risk: long-term immunosuppression raises squamous cell skin cancer (the commonest solid malignancy in long-term recipients), cervical, colon and post-transplant lymphoproliferative disorder (PTLD) — EBV-driven B-cell proliferation managed first by reducing immunosuppression, then rituximab or chemotherapy.
- Drug interactions that change surgical decisions: fluconazole and other azoles (CYP3A4 inhibition) raise calcineurin-inhibitor toxicity; rifampicin and phenytoin precipitate rejection by dropping levels; NSAIDs compound nephrotoxicity.
- Practical ward rules: continue maintenance drugs through surgery (with stress-dose steroid cover where indicated), treat fever vigorously with a low threshold for cultures, avoid intramuscular injections in thrombocytopenic recipients, and involve the transplant physician before adding or stopping anything.
Working through a surgical admission
A renal transplant recipient of four years presents with right iliac fossa pain; the graft is on the other side. The differential runs appendicitis versus lymphocele versus PTLD versus opportunistic infection, and none of these presents classically because steroids blunt signs. Path: full examination, urine and blood cultures, tacrolimus trough, ultrasound then CT. Appendicitis confirmed — surgery proceeds with laparoscopic appendicectomy, prophylaxis tailored with the microbiologist (avoiding a needless nephrotoxic aminoglycoside), tacrolimus given via nasogastric tube on schedule, steroid cover for moderate surgical stress, and mycophenolate continued. Post-op, the team watches for delayed flatus, wound seroma and a fever that could be wound infection, CMV or both; leucopenia prompts mycophenolate dose review, not automatic cessation, and any change is co-signed by the transplant unit. Had the presentation been a chronically discharging wound at three months, the answer changes: consider atypical mycobacteria and CMV, biopsy before broadening antibiotics, and if it were a tonsillar mass with fever, reduce immunosuppression and biopsy for PTLD.
Perspective: how the exam asks it
The theory paper strips this topic into matching-type questions: drug to side effect (tacrolimus-diabetes, ciclosporin-hirsutism, sirolimus-bad wounds, azathioprine-allopurinol interaction), and timeline to organism (1-6 months equals CMV and PCP). The clinical vignette usually hides a transplant in the history's last line — "status post renal transplant, on tacrolimus" — and expects you to modify the whole answer, not just the antibiotic: blunted abdominal signs, delayed diagnosis, higher threshold for imaging to surgery, and nephrotoxin avoidance. Indian practice supplies two recurring contexts: post-transplant tuberculosis, far commoner than in Western series and screened for with prophylaxis debates, and live-related donation under the Transplantation of Human Organs Act, where the surgery and the immunosuppression are governed by NOTTO-linked documentation — both are legitimate viva extensions.
Frequently asked questions
What is standard maintenance immunosuppression after solid organ transplantation?
Triple therapy with a calcineurin inhibitor (usually tacrolimus), an antiproliferative (mycophenolate or azathioprine) and low-dose prednisolone, guided by trough levels.
Why must azathioprine be reduced with allopurinol?
Allopurinol inhibits xanthine oxidase, blocking degradation of azathioprine's active metabolite 6-mercaptopurine; toxicity and marrow suppression follow unless the dose is cut to roughly a quarter.
Which infections dominate the first six months after transplant?
Opportunistic infections — cytomegalovirus, pneumocystis (prevented by co-trimoxazole), BK virus and fungi — alongside rejection-treatment infections; month one is mainly surgical.
What is post-transplant lymphoproliferative disorder?
An EBV-driven B-cell lymphoproliferation managed initially by reducing immunosuppression, with rituximab-chemotherapy reserved for progressive disease.
How should immunosuppression be handled when a transplant recipient needs surgery?
Continue the usual regimen through the peri-operative period, add steroid stress cover as appropriate, hold mTOR inhibitors when wound or anastomotic healing is critical, and avoid nephrotoxins and interacting drugs in consultation with the transplant team.